Effect of treatment on Campylobacter pylori in peptic disease: a randomised prospective trial

Gut. 1988 Mar;29(3):279-83. doi: 10.1136/gut.29.3.279.

Abstract

This study investigated the effect of colloidal bismuth subcitrate and cimetidine on Campylobacter pylori in peptic disease. In 74% of 135 patients with peptic disease diagnosed at endoscopy C pylori was detected before treatment. Compared with cimetidine, colloidal bismuth subcitrate significantly decreased the incidence of C pylori after six weeks of treatment (p less than 0.001). In the colloidal bismuth subcitrate group, subsequent healing of the lesion was correlated with the clearance of C pylori, unlike in the cimetidine group. C pylori was strongly associated with the presence of histological gastritis, which was decreased by colloidal bismuth subcitrate (p less than 0.001).

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Campylobacter Infections / complications
  • Campylobacter Infections / drug therapy*
  • Cimetidine / therapeutic use*
  • Drug Therapy, Combination
  • Esophagitis / drug therapy
  • Esophagitis / etiology
  • Female
  • Gastritis / drug therapy
  • Gastritis / etiology
  • Humans
  • Male
  • Organometallic Compounds / therapeutic use*
  • Peptic Ulcer / drug therapy*
  • Peptic Ulcer / etiology
  • Prospective Studies
  • Random Allocation

Substances

  • Organometallic Compounds
  • Cimetidine
  • bismuth tripotassium dicitrate